ADVIA Centaur EBV-EBNA IgG— 510(k) K233605

Substantially Equivalent

Biokit, S.A.

FDA 510(k) clearance K233605 for ADVIA Centaur EBV-EBNA IgG, Substantially Equivalent on 2024-08-07. Applicant: Biokit, S.A..

Clearance details

Applicant: Biokit, S.A.
Product code: Code LLM
Advisory panel: Microbiology
Date received: 2023-11-09
Decision date: 2024-08-07
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Lliçà DAmunt, Barcelona, ES

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.